MUZAFFAR H QAZILBASH to Thalidomide
This is a "connection" page, showing publications MUZAFFAR H QAZILBASH has written about Thalidomide.
Connection Strength
0.686
-
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
Score: 0.113
-
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.
Score: 0.107
-
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8.
Score: 0.095
-
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1183-9.
Score: 0.090
-
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
Score: 0.079
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
Score: 0.063
-
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
Score: 0.028
-
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396.
Score: 0.026
-
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.025
-
Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. 2014 Mar; 49(3):422-5.
Score: 0.022
-
Fifty years of melphalan use in hematopoietic stem cell?transplantation. Biol Blood Marrow Transplant. 2013 Mar; 19(3):344-56.
Score: 0.020
-
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec; 12(13):1195-203.
Score: 0.019